ArticleCPT: pharmacometrics & systems pharmacology2022

Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma.

Joanna C Masters et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.